Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs

Gilead Sciences’ oral chronic hepatitis C treatments Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir) will be hit with large reductions in their NHI prices under the “huge seller” re-pricing rule in this April’s NHI price revision. An official in charge...read more